Leveraging Disease Relevant Transcriptomes From TOPMed LTRC Improves Polygenic Transcriptome Risk Prediction for COPD
Rattachement africain : us, se. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract RATIONALE: Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of mortality worldwide. We previously published the polygenic transcriptome risk score (PTRS) which uses the cumulative effect of predicted gene expression to construct genetic predictors for complex diseases, and we demonstrated the value of PTRS for COPD built on Genotype-Tissue Expression (GTEx) Lung tissue with significantly improved cross-ancestry portability. However, the postmortem collection and lack of lung disease status on GTEx samples likely affect results. We hypothesized that the performance of PTRS will be improved by using disease-relevant expression quantitative trait loci (eQTLs) to construct the score. Here, we aimed to improve performance of PTRS by leveraging disease-relevant eQTLs. METHODS: We constructed two transcriptome prediction models, Elastic Net (EN) and Prediction Using Models Informed by Chromatin conformation and Epigenomics (PUMICE), using TOPMed lung RNA-seq data from the Lung Tissue Research Consortium (LTRC), which included COPD patients undergoing lung surgery. We compared their performance with two published models built on RNA-seq from GTEx Lung tissue, GTEx-EN and GTEx-PUMICE. We first integrated each of four transcriptome models with multi-ancestry GWAS of FEV1/FVC ratio (Shrine et al. 2023) to generate transcriptome-wide association study (TWAS) results, which produced trait-associated genes. Pathway analysis was then conducted on significant TWAS genes. Finally, the PTRS was computed on TWAS genes that were included in the top 20 significantly enriched pathways. We tested performance of PTRS in race-stratified analysis for moderate-to-severe and severe COPD in COPDGene. RESULTS: Our models produced more significant TWAS genes (FDR<0.05) and had more overlaps with genes identified for FEV1/FVC ratio from Shrine et al. 2023 compared to two GTEx models (Fig. A). Additionally, our models had significantly higher AUC for predicting both moderate-to-severe and severe COPD in race-stratified analysis. The mean AUC from LTRC-EN for predicting severe COPD was 0.57 and 0.55 respectively for EUR and AFA, which was significantly higher than mean AUC of 0.54 and 0.51 from GTEx-EN (Delong p-value=8.15x10-10 for EUR and 1.42x10-3 for AFA) (Fig. B). Similarly, the PTRS derived from our models produced higher Odds Ratios (OR) per standard deviation. The mean OR from LTRC-PUMICE for moderate-to-severe COPD was 1.25 and 1.18 respectively for EUR and AFA, while it was 1.17 and 1.12 from GTEx-PUMICE (Fig. C). CONCLUSIONS: Our study demonstrates the value of leveraging disease-relevant RNA-seq to construct transcriptome prediction models and their improvement on identifying lung function genes and predicting COPD across ancestries.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Leveraging Disease Relevant Transcriptomes From TOPMed LTRC Improves Polygenic Transcriptome Risk Prediction for COPD
- Date Crossref
- 01/05/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Virginia pays non établi dans la noticeUniversité ou école supérieure
-
Vision Technology (United States) pays non établi dans la noticeEntreprise
-
Penn State Milton S. Hershey Medical Center pays non établi dans la noticeÉtablissement de santé
-
KTH Royal Institute of Technology pays non établi dans la noticeUniversité ou école supérieure
-
Broad Institute pays non établi dans la noticeOrganisation à but non lucratif
-
University of Colorado Anschutz pays non établi dans la noticeUniversité ou école supérieure
-
UCLA Medical Center pays non établi dans la noticeÉtablissement de santé
-
Harbor–UCLA Medical Center pays non établi dans la noticeÉtablissement de santé
-
Mayo Clinic in Arizona Department of Medicine pays non établi dans la noticeÉtablissement de santé
-
Loyola University Chicago pays non établi dans la noticeUniversité ou école supérieure
-
University of Chicago pays non établi dans la noticeUniversité ou école supérieure
-
Columbia University Irving Medical Center pays non établi dans la noticeÉtablissement de santé
University of Virginia, Vision Technology (United States) et Penn State Milton S. Hershey Medical Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.